Durata Therapeutics Presents New Data for DALVANCE(TM) at IDWeek 2014(TM)
October 10, 2014 13:34 ET
|
Durata Therapeutics, Inc.
CHICAGO, Oct. 10, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) today announced a summary of presentation data from its recently launched product, DALVANCE™ (dalbavancin) for...
FDA Grants Durata Therapeutics a Special Protocol Agreement (SPA) for Its Phase 3 Study of DALVANCE(TM) in Hospitalized Community-Acquired Pneumonia
October 03, 2014 08:00 ET
|
Durata Therapeutics, Inc.
CHICAGO, Oct. 3, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) today announced that the Company has received a Special Protocol Agreement (SPA) from the Food and Drug Administration (FDA)...
Durata Therapeutics to Present Five Posters at IDWeek 2014
October 02, 2014 09:00 ET
|
Durata Therapeutics, Inc.
CHICAGO, Oct. 2, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) today announced that it will present five posters highlighting data from its recently launched product, DALVANCE™...
Durata Therapeutics Presented Data at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
September 09, 2014 09:00 ET
|
Durata Therapeutics, Inc.
CHICAGO, Sept. 9, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced that data from its recently launched product, DALVANCE™ (dalbavancin) for injection, was...
Durata Therapeutics to Present Safety and Efficacy Data at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
September 03, 2014 09:00 ET
|
Durata Therapeutics, Inc.
CHICAGO, Sept. 3, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) today announced that that it will present seven posters highlighting safety and efficacy data from its recently launched...
Durata Therapeutics Names Wendy Yarno and J. Martin Carroll to Its Board of Directors
August 26, 2014 17:00 ET
|
Durata Therapeutics, Inc.
CHICAGO, Aug. 26, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) today announced that Wendy Yarno and Marty Carroll were added to its Board of Directors at a quarterly meeting of the Board...
Durata Therapeutics Reports Second Quarter 2014 Financial Results
August 07, 2014 07:00 ET
|
Durata Therapeutics, Inc.
CHICAGO, Aug. 7, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced financial results for the quarter ended June 30, 2014.
"This was a very busy and exciting quarter...
Durata Therapeutics to Present at Upcoming Investor Conference
August 06, 2014 08:30 ET
|
Durata Therapeutics, Inc.
CHICAGO, Aug. 6, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) announced today that Paul R. Edick, Chief Executive Officer, will present at the Wedbush 2014 Life Sciences Management...
Durata Therapeutics to Report Second Quarter 2014 Financial Results on August 7, 2014
July 31, 2014 08:30 ET
|
Durata Therapeutics, Inc.
CHICAGO, July 31, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) has scheduled its quarterly conference call for Thursday, August 7 at 8:30 a.m. Eastern Time to discuss second...
Durata Therapeutics Enters Into an Exclusive License and Supply Agreement With Angelini to Commercialize Dalbavancin in Certain European Territories, Russia and Turkey
July 30, 2014 08:30 ET
|
Durata Therapeutics, Inc.
CHICAGO, July 30, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) announced today that its Dutch subsidiary, Durata Therapeutics International B.V., has entered into a license and...